Enlarged perivascular spaces and florbetapir uptake in patients with intracerebral hemorrhage.


Journal

European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 03 05 2019
accepted: 16 07 2019
pubmed: 31 7 2019
medline: 21 10 2020
entrez: 31 7 2019
Statut: ppublish

Résumé

Enlarged perivascular spaces in the centrum semiovale (CSO-EPVS) have been linked to cerebral amyloid angiopathy (CAA). To get insight into the underlying mechanisms of this association, we investigated the relationship between amyloid-β deposition assessed by 18F-florbetapir PET and CSO-EPVS in patients with acute intracerebral hemorrhage (ICH). We prospectively enrolled 18 patients with lobar ICH (suggesting CAA) and 20 with deep ICH (suggesting hypertensive angiopathy), who underwent brain MRI and 18F-florbetapir PET. EPVS were assessed on MRI using a validated 4-point visual rating scale in the centrum semiovale and the basal ganglia (BG-EPVS). PET images were visually assessed, blind to clinical and MRI data. We evaluated the association between florbetapir PET positivity and high degree (score> 2) of CSO-EPVS and BG-EPVS. High CSO-EPVS degree was more common in patients with lobar ICH than deep ICH (55.6% vs. 20.0%; p = 0.02). Eight (57.1%) patients with high CSO-EPVS degree had a positive florbetapir PET compared with 4 (16.7%) with low CSO-EPVS degree (p = 0.01). In contrast, prevalence of florbetapir PET positivity was similar between patients with high vs. low BG-EPVS. In multivariable analysis adjusted for age, hypertension, and MRI markers of CAA, florbetapir PET positivity (odds ratio (OR) 6.44, 95% confidence interval (CI) 1.32-38.93; p = 0.03) was independently associated with high CSO-EPVS degree. Among patients with spontaneous ICH, high degree of CSO-EPVS but not BG-EPVS is associated with amyloid PET positivity. The findings provide further evidence that CSO-EPVS are markers of vascular amyloid burden that may be useful in diagnosing CAA.

Identifiants

pubmed: 31359110
doi: 10.1007/s00259-019-04441-1
pii: 10.1007/s00259-019-04441-1
doi:

Substances chimiques

Amyloid beta-Peptides 0
Aniline Compounds 0
Ethylene Glycols 0
florbetapir 6867Q6IKOD

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2339-2347

Références

Stroke. 2010 Nov;41(11):2483-90
pubmed: 20864661
Neurology. 2016 Nov 8;87(19):2043-2049
pubmed: 27605173
Lancet Neurol. 2010 Jul;9(7):689-701
pubmed: 20610345
J Cereb Blood Flow Metab. 2016 Mar;36(3):576-80
pubmed: 26661250
N Engl J Med. 2001 May 10;344(19):1450-60
pubmed: 11346811
Brain. 2017 Apr 1;140(4):1107-1116
pubmed: 28335021
Brain. 2015 Aug;138(Pt 8):2126-39
pubmed: 26115675
Neurology. 2014 Jan 7;82(1):57-62
pubmed: 24285616
Int Psychogeriatr. 2004 Sep;16(3):275-93
pubmed: 15559753
Neurology. 2006 Jan 24;66(2):206-9
pubmed: 16434655
Lancet Neurol. 2013 Aug;12(8):822-38
pubmed: 23867200
J Neurol Neurosurg Psychiatry. 2013 Jun;84(6):624-9
pubmed: 23412074
AJR Am J Roentgenol. 1987 Aug;149(2):351-6
pubmed: 3496763
J Neurol Neurosurg Psychiatry. 2012 Feb;83(2):124-37
pubmed: 22056963
Stroke. 2018 Aug;49(8):1913-1919
pubmed: 30012821
Lancet Neurol. 2013 May;12(5):483-97
pubmed: 23602162
Brain Pathol. 2014 Jul;24(4):396-403
pubmed: 24946077
Neurology. 2015 Dec 1;85(22):1930-6
pubmed: 26537052
Brain Pathol. 2015 Jan;25(1):63-78
pubmed: 25521178
Lancet Neurol. 2009 Feb;8(2):165-74
pubmed: 19161908
Neurology. 2010 Aug 24;75(8):693-8
pubmed: 20733144
Neurology. 2010 Feb 9;74(6):487-93
pubmed: 20142615
Neurology. 2013 Apr 23;80(17):1551-6
pubmed: 23553482
Stroke. 2015 Jun;46(6):1707-9
pubmed: 25908461
Neurology. 2017 Aug 15;89(7):697-704
pubmed: 28724587
Neurology. 2017 Mar 21;88(12):1157-1164
pubmed: 28228568
Neurology. 2010 Apr 27;74(17):1346-50
pubmed: 20421578
J Neurol Neurosurg Psychiatry. 2004 Nov;75(11):1519-23
pubmed: 15489380
Stroke. 2010 Mar;41(3):450-4
pubmed: 20056930
Alzheimers Dement. 2013 Oct;9(5 Suppl):S72-83
pubmed: 23375563

Auteurs

Nicolas Raposo (N)

Department of Neurology, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Place Baylac, 31059, Toulouse Cedex 9, France. raposo.n@chu-toulouse.fr.
Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France. raposo.n@chu-toulouse.fr.

Mélanie Planton (M)

Department of Neurology, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Place Baylac, 31059, Toulouse Cedex 9, France.
Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France.

Pierre Payoux (P)

Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France.
Department of Nuclear Medicine, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.

Patrice Péran (P)

Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France.

Jean François Albucher (JF)

Department of Neurology, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Place Baylac, 31059, Toulouse Cedex 9, France.
Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France.

Lionel Calviere (L)

Department of Neurology, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Place Baylac, 31059, Toulouse Cedex 9, France.
Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France.

Alain Viguier (A)

Department of Neurology, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Place Baylac, 31059, Toulouse Cedex 9, France.
Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France.

Vanessa Rousseau (V)

Department of Epidemiology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.

Anne Hitzel (A)

Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France.
Department of Nuclear Medicine, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.

François Chollet (F)

Department of Neurology, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Place Baylac, 31059, Toulouse Cedex 9, France.
Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France.

Jean Marc Olivot (JM)

Department of Neurology, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Place Baylac, 31059, Toulouse Cedex 9, France.
Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France.

Fabrice Bonneville (F)

Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France.
Department of Neuroradiology, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.

Jérémie Pariente (J)

Department of Neurology, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Place Baylac, 31059, Toulouse Cedex 9, France.
Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH